Project Grant K01CA316937
Award Date 9/2/26
Completion Date 8/31/31
Dollars Obligated $177K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Weill Medical College of Cornell University $733,149 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate immune-related adverse events (IRAE) driven by anti-PD1 immunotherapy in cancer patients. The research integrates patient-centered clinical investigation with advanced omics pipelines using human specimens, leveraging a multidisciplinary approach spanning human and mouse tissue and tumor immunology. The...
- The National Cancer Institute awarded Weill Medical College of Cornell University $694,133 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how sympathetic nervous system axons control melanoma progression and interact with immune effectors in the tumor microenvironment. The research focuses on defining the role of sympathetic axons in inhibiting melanoma growth through norepinephrine signaling via adrenergic receptors on immune cells, particularly...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $697,131 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate myeloid-stromal interactions that drive immune suppression in colorectal cancer and to evaluate therapeutic strategies targeting these pathways. The research addresses the immunological resistance of microsatellite-stable colorectal cancer to immune checkpoint blockade, particularly in patients with liver metastases. The...
- The National Cancer Institute awarded Weill Medical College of Cornell University $703,423 on a Project Grant (R01CA306020) effective June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The award funds research to identify molecular targets for mitigating immune-related adverse events (IRAEs) triggered by immunotherapy, particularly immune checkpoint blockade agents used in cancer treatment. IRAEs occur in 20–30 percent of cancer patients receiving these agents, with skin and...
- The National Cancer Institute awarded $435,243 to Weill Medical College of Cornell University on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate GSK3 relocalizing peptides as anti-cancer therapeutics. The recipient will assess the anti-cancer efficacy of GSK3 RNLS-peptide both as a standalone therapy and in combination with the chemotherapeutic agent 5-fluorouracil. The work employs multiple orthotopic mouse models of lung, brain, and colorectal...
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded Yale University $130,490 on June 1, 2026, to support research on cellular and molecular mechanisms of early-onset colorectal cancer under the Cancer Research Manpower program (CFDA 93.398). The award is a Project Grant with a period of performance through May 31, 2028, and work is performed in New Haven, Connecticut. The Cancer Research Manpower program provides biomedical training opportunities for individuals pursuing careers in basic, clinical, and...
- The National Institutes of Health National Cancer Institute awarded Weill Medical College of Cornell University $198,164 on September 26, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research into genomic instability mechanisms in lung cancer driven by the APOBEC3 family of cytosine deaminases. The award funds investigation of APOBEC3 (A3) mutagenesis in lung adenocarcinoma, with research activities centered on identifying which specific A3 family members...
- The National Cancer Institute awarded Weill Medical College of Cornell University $724,256 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a systemic theranostic alpha-radioimmunotherapy platform for advanced colorectal cancer. The project establishes an optimized pretargeted radioimmunotherapy (PRIT) platform using the 203PB/212PB theranostic pair, which pairs lead isotopes with matched half-lives—2.2 days for imaging and 10.6 hours for therapy—to...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...